Top

Journal of Gastrointestinal Cancer

Published in:

01-12-2011 | Original Research

Immunohistochemical Detection of Autotaxin (ATX)/Lysophospholipase D (lysoPLD) in Submucosal Invasive Colorectal Cancer

Authors: Shinsuke Kazama, Joji Kitayama, Junken Aoki, Ken Mori, Hirokazu Nagawa

Published in: Journal of Gastrointestinal Cancer | Issue 4/2011

Abstract

Purpose

Autotaxin (ATX) is molecularly identical to lysophospholipase D (lysoPLD) and is a main enzyme producing lysophosphatidic acid (LPA), which mediates a broad range of cellular responses including stimulation of cell motility.

Patients and Methods

Using immunohistochemical staining, we examined the expression of ATX/lysoPLD in 98 cases of early colorectal cancer with submucosal invasion. ATX/lysoPLD was highly expressed in infiltrating cells in tumor tissue in the submucosal layer, which were characterized as mast cells.

Results

The number of ATX/lysoPLD-positive cells was significantly greater in tumors with a macroscopically depressed lesion than in tumors without depression. The density of ATX/lysoPLD-positive cells tended to have a positive correlation with microvessel vascular density (MVD), while it was not correlated with vessel invasion and nodal metastases as well as lymphovascular vessel density (LVD).

Conclusion

Our results suggest that local production of LPA through ATX/lysoPLD may weakly correlate with formation of a depressive lesion and tumor angiogenesis in the early stage of colorectal cancer.

Liotta LA, Guirguis RA, Schiffmann E. Tumor autocrine motility factor. Prog Clin Biol Res. 1986;212:17–24.PubMed

Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffmann E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem. 1989;264(36):21544–9.PubMed

Matsumoto K, Nakamura T, Kramer RH. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem. 1994;269(50):31807–13.PubMed

Stracke ML, Clair T, Liotta LA. Autotaxin, tumor motility-stimulating exophosphodiesterase. Adv Enzyme Regul. 1997;37:135–44.PubMedCrossRef

Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992;267(4):2524–9.PubMed

Lee HY, Clair T, Mulvaney PT, Woodhouse EC, Aznavoorian S, Liotta LA, et al. Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin. J Biol Chem. 1996;271(40):24408–12.PubMedCrossRef

Stefan C, Gijsbers R, Stalmans W, Bollen M. Differential regulation of the expression of nucleotide pyrophosphatases/phosphodiesterases in rat liver. Biochim Biophys Acta. 1999;1450(1):45–52.PubMedCrossRef

Kawagoe H, Soma O, Goji J, Nishimura N, Narita M, Inazawa J, et al. Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Genomics. 1995;30(2):380–4.PubMedCrossRef

Deissler H, Lottspeich F, Rajewsky MF. Affinity purification and cDNA cloning of rat neural differentiation and tumor cell surface antigen gp130RB13-6 reveals relationship to human and murine PC-1. J Biol Chem. 1995;270(17):9849–55.PubMedCrossRef

10.

MacDonald NJ, Freije JM, Stracke ML, Manrow RE, Steeg PS. Site-directed mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem. 1996;271(41):25107–16.PubMedCrossRef

11.

Mulvaney PT, Stracke ML, Nam SW, Woodhouse E, O'Keefe M, Clair T, et al. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. Int J Cancer. 1998;78(1):46–52.PubMedCrossRef

12.

Kawagoe H, Stracke ML, Nakamura H, Sano K. Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Res. 1997;57(12):2516–21.PubMed

13.

Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001;61(18):6938–44.PubMed

14.

Tokumura A, Tominaga K, Yasuda K, Kanzaki H, Kogure K, Fukuzawa K. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors. Cancer. 2002;94(1):141–51.PubMedCrossRef

15.

Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, et al. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem. 2004;92(6):1115–40.PubMedCrossRef

16.

Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277(50):48737–44.PubMedCrossRef

17.

Tokumura A, Fujimoto H, Yoshimoto O, Nishioka Y, Miyake M, Fukuzawa K. Production of lysophosphatidic acid by lysophospholipase D in incubated plasma of spontaneously hypertensive rats and Wistar Kyoto rats. Life Sci. 1999;65(3):245–53.PubMedCrossRef

18.

Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J. 1998;12(15):1589–98.PubMed

19.

Yuelling LM, Fuss B. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim Biophys Acta. 2008;1781(9):525–30.PubMed

20.

Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009;48(9):801–9.PubMedCrossRef

21.

Narita M, Goji J, Nakamura H, Sano K. Molecular cloning, expression, and localization of a brain-specific phosphodiesterase I/nucleotide pyrophosphatase (PD-I alpha) from rat brain. J Biol Chem. 1994;269(45):28235–42.PubMed

22.

Lee HY, Murata J, Clair T, Polymeropoulos MH, Torres R, Manrow RE, et al. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun. 1996;218(3):714–9.PubMedCrossRef

23.

Mori K, Kitayama J, Aoki J, Kishi Y, Shida D, Yamashita H, et al. Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD). Virchows Arch. 2007;451(1):47–56.PubMedCrossRef

24.

Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol. 2004;39(6):534–43.PubMedCrossRef

25.

Sasaki M, Watanabe H, Jass JR, Ajioka Y, Kobayashi M, Hatakeyama K. Immunoperoxidase staining for cytokeratins 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: a comparison with genetic analysis of K-ras. Histopathology. 1998;32(3):199–208.PubMedCrossRef

26.

Tanaka M, Kishi Y, Takanezawa Y, Kakehi Y, Aoki J, Arai H. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett. 2004;571(1–3):197–204.PubMedCrossRef

27.

Baumforth KR, Flavell JR, Reynolds GM, Davies G, Pettit TR, Wei W, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood. 2005;106(6):2138–46.PubMedCrossRef

28.

Savaskan NE, Rocha L, Kotter MR, Baer A, Lubec G, van Meeteren LA, et al. Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. Cell Mol Life Sci. 2007;64(2):230–43.PubMedCrossRef

29.

Gao J, Knutsen A, Arbman G, Carstensen J, Franlund B, Sun XF. Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis. 2009;41(2):116–22.PubMedCrossRef

30.

Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94(12):1823–32.PubMedCrossRef

31.

Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94(2):293–8.PubMedCrossRef

32.

Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63(3):539–43.PubMedCrossRef

33.

Hermanek P, Hutter RV, Sobin LH, Wittekind C, International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer. 1999;86(12):2668–73.PubMedCrossRef

34.

Sengupta S, Wang Z, Tipps R, Xu Y. Biology of LPA in health and disease. Semin Cell Dev Biol. 2004;15(5):503–12.PubMedCrossRef

35.

Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6(2):135–42.PubMedCrossRef

36.

Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech. 2003;60(1):64–9.PubMedCrossRef

37.

Noël A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol. 2008;19(1):52–60.PubMedCrossRef

38.

Morris GP, Beck P, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96(3):795–803.PubMed

39.

Fox CC, Lichtenstein L, Roche JK. Intestinal mast cell responses in idiopathic inflammatory bowel disease. Histamine release from human intestinal mast cells in response to gut epithelial proteins. Dig Dis Sci. 1993;38(6):1105–12.PubMedCrossRef

40.

Sun B, Nishihira J, Suzuki M, Fukushima N, Ishibashi T, Kondo M, et al. Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. Int J Mol Med. 2003;12(4):633–41.PubMed

41.

Lee J, Park S, Lee EK, Park CG, Chung HC, Rha SY, et al. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res. 2006;12(21):6351–8.PubMedCrossRef

42.

Rivera-Lopez CM, Tucker A, Lynch KR. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis. 2008;11(3):301–10.PubMedCrossRef

43.

van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26(13):5015–22.PubMedCrossRef

44.

Lin CI, Chen C, Huang MT, Lee SJ, Lin CH, Chang CC, et al. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci. 2008;65(17):2740–51.PubMedCrossRef

45.

An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem. 1998;273(14):7906–10.PubMedCrossRef

46.

Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA. 2000;97(24):13384–9.PubMedCrossRef

Title: Immunohistochemical Detection of Autotaxin (ATX)/Lysophospholipase D (lysoPLD) in Submucosal Invasive Colorectal Cancer
Authors: Shinsuke Kazama
Joji Kitayama
Junken Aoki
Ken Mori
Hirokazu Nagawa
Publication date: 01-12-2011
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 4/2011
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-010-9186-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2011

Non-Viral Causes of Hepatocellular Carcinoma

Comparison of Cancer Care for Hepatocellular Carcinoma at Two Tertiary-Care Referral Centers from High and Low Endemic Regions for Viral Hepatitis

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

Budd–Chiari Syndrome in Pleural Mesothelioma

Solitary Subcutaneous Metastasis from Squamous Cell Carcinoma of the Esophagus: A Case Report and Brief Review of Literature

Chemoradiation for Unresectable Gall Bladder Cancer: Time to Review Historic Nihilism?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials